Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. OCC
OCC logo

OCC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Optical Cable Corp (OCC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
7.260
1 Day change
18.82%
52 Week Range
11.500
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Optical Cable Corp (OCC) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows a slight pre-market price increase, the lack of significant trading signals, weak financial performance, and absence of positive catalysts suggest that it is better to hold off on investing in this stock right now.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 59.705, and moving averages are converging, indicating no strong trend. The stock is trading near its resistance level (R1: 6.688), suggesting limited immediate upside potential.

Positive Catalysts

  • The stock has a 7.76% chance of increasing in the next month based on similar candlestick patterns.

Neutral/Negative Catalysts

  • Weak financial performance in the latest quarter, including a significant drop in net income (-86.98% YoY) and EPS (-80.00% YoY). No recent news or significant insider/hedge fund activity. Analysts' ratings and price targets are unrelated to OCC.

Financial Performance

In Q4 2025, revenue increased slightly by 1.76% YoY, but net income and EPS dropped significantly (-86.98% and -80.00% YoY, respectively). Gross margin also declined by 4.97%, indicating weaker profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No relevant analyst ratings or price targets for OCC. The provided analyst rating is for a different company, Orthocell, and does not apply here.

Wall Street analysts forecast OCC stock price to rise
Analyst Rating
0
Wall Street analysts forecast OCC stock price to rise
Buy
Hold
Sell
0
Current: 6.110
sliders
Low
0
Averages
0
High
0
0
Current: 6.110
sliders
Low
0
Averages
0
High
0
Canaccord
Shane Storey
Speculative Buy
initiated
$1.33
AI Analysis
2025-12-17
Reason
Canaccord
Shane Storey
Price Target
$1.33
AI Analysis
2025-12-17
initiated
Speculative Buy
Reason
Canaccord analyst Shane Storey initiated coverage of Orthocell with a Speculative Buy rating and A$1.33 price target. The regenerative medicine company is commercializing novel collagen-based devices for peripheral nerve repair, including its flagship product, Remplir, the analyst tells investors. Recently achieved key global clearances, including FDA 510(k) clearance in April, position the company "at the start of a multi-year commercial expansion," the analyst added.

People Also Watch